1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Syntrix Biosystems, Inc. - Product Pipeline Review - 2015

Syntrix Biosystems, Inc. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 28 pages

Syntrix Biosystems, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Syntrix Biosystems, Inc. - Product Pipeline Review - 2015’, provides an overview of the Syntrix Biosystems, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Syntrix Biosystems, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Syntrix Biosystems, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Syntrix Biosystems, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Syntrix Biosystems, Inc.’s pipeline products

Reasons to buy

- Evaluate Syntrix Biosystems, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Syntrix Biosystems, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Syntrix Biosystems, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Syntrix Biosystems, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Syntrix Biosystems, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Syntrix Biosystems, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Syntrix Biosystems, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Syntrix Biosystems, Inc. Snapshot 5
Syntrix Biosystems, Inc. Overview 5
Key Information 5
Key Facts 5
Syntrix Biosystems, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Syntrix Biosystems, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Syntrix Biosystems, Inc. - Pipeline Products Glance 10
Syntrix Biosystems, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Syntrix Biosystems, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Syntrix Biosystems, Inc. - Drug Profiles 14
aminopterin sodium 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Omnitram 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
SX-517 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
SX-682 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Small Molecules to Inhibit Dihydrofolate Synthetase for MDR/XDR TB 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
SX-576 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Syntrix Biosystems, Inc. - Pipeline Analysis 21
Syntrix Biosystems, Inc. - Pipeline Products by Route of Administration 21
Syntrix Biosystems, Inc. - Pipeline Products by Molecule Type 22
Syntrix Biosystems, Inc. - Pipeline Products by Mechanism of Action 23
Syntrix Biosystems, Inc. - Recent Pipeline Updates 24
Syntrix Biosystems, Inc. - Dormant Projects 25
Syntrix Biosystems, Inc. - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
Syntrix Biosystems, Inc., Key Information 5
Syntrix Biosystems, Inc., Key Facts 5
Syntrix Biosystems, Inc. - Pipeline by Indication, 2015 7
Syntrix Biosystems, Inc. - Pipeline by Stage of Development, 2015 8
Syntrix Biosystems, Inc. - Monotherapy Products in Pipeline, 2015 9
Syntrix Biosystems, Inc. - Phase II, 2015 10
Syntrix Biosystems, Inc. - Phase I, 2015 11
Syntrix Biosystems, Inc. - Preclinical, 2015 12
Syntrix Biosystems, Inc. - Discovery, 2015 13
Syntrix Biosystems, Inc. - Pipeline by Route of Administration, 2015 21
Syntrix Biosystems, Inc. - Pipeline by Molecule Type, 2015 22
Syntrix Biosystems, Inc. - Pipeline Products by Mechanism of Action, 2015 23
Syntrix Biosystems, Inc. - Recent Pipeline Updates, 2015 24
Syntrix Biosystems, Inc. - Dormant Developmental Projects,2015 25

List of Figures
Syntrix Biosystems, Inc. - Pipeline by Top 10 Indication, 2015 7
Syntrix Biosystems, Inc. - Pipeline by Stage of Development, 2015 8
Syntrix Biosystems, Inc. - Monotherapy Products in Pipeline, 2015 9
Syntrix Biosystems, Inc. - Pipeline by Top 10 Route of Administration, 2015 21
Syntrix Biosystems, Inc. - Pipeline by Top 10 Molecule Type, 2015 22
Syntrix Biosystems, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.